8-K: Harvard Apparatus Regenerative Tech Raises Capital

Harvard Apparatus Regenerative Technology, Inc. has entered into securities purchase agreements to raise capital through a private placement, with its CEO converting outstanding notes.

Summary

• Harvard Apparatus Regenerative Technology, Inc. (the Company) entered into Securities Purchase Agreements with investors on September 11, 2026, for a private placement.
• The Company sold an aggregate of 2,703,727 shares of common stock for a total purchase price of $2,838,911, at a price of $1.05 per share.
• The private placement closed on the same day, September 11, 2026.
• Included in this placement, CEO Jerry (Junli) He purchased 683,725 shares by converting $717,911 of outstanding principal and accrued interest from bridge promissory notes previously issued to him.
• These shares were also issued at the $1.05 per share price, and the notes were fully cancelled.
• The agreements contain standard representations, warranties, and covenants, and the sale was conducted under exemptions from registration, relying on Section 4(a)(2) and Rule 506 of the Securities Act.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative development due to the dilutive nature of the capital raise, although the conversion of debt by the CEO mitigates some concern.

Positives

• The company successfully raised capital through a private placement.
• The CEO converted outstanding debt into equity, demonstrating personal investment and reducing the company's debt burden.
• The transaction was completed quickly on the same day it was agreed upon.
• The sale was structured under exemptions from registration, indicating compliance with securities regulations for private placements.

Negatives

• The issuance of new shares dilutes existing shareholders' ownership.
• The capital raise was conducted through a private placement, which typically involves restricted securities not freely tradable.
• The company's reliance on private placements and debt conversion may indicate ongoing financial pressures.

Risks

• The issuance of new shares can dilute the earnings per share and voting power of existing shareholders.
• The securities purchased are restricted and may not be easily resold, impacting liquidity for investors.
• The company's financial health may require continuous capital infusions, potentially leading to further dilution or debt.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the immediate transaction. The company's ability to maintain its listing on a trading market and potential future reverse stock splits are mentioned as considerations.

Management Comments

• The form of Purchase Agreement is included to provide investors with information regarding the terms of the transaction, not to provide other factual information regarding the Company.
• Stockholders should not rely on the representations, warranties, or descriptions thereof as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries or affiliates.
• Information concerning the subject matter of the representations and warranties may change after the date of the Purchase Agreement, which subsequent information may or may not be fully reflected in public disclosures.

Industry Context

StockSavvy.ai notes that private placements and debt-to-equity conversions are common strategies for early-stage or financially constrained companies to raise capital without the complexities of public offerings. However, they often lead to share dilution and can signal a need for immediate funding.

Related Party Transactions

• CEO Jerry (Junli) He purchased 683,725 shares of common stock by converting $717,911 of outstanding principal and accrued interest from bridge promissory notes previously issued by the Company to him.

Stakeholder Impact

• Existing shareholders will experience dilution due to the issuance of new shares.
• Investors in the private placement will hold restricted securities, limiting their immediate ability to sell.
• The conversion of debt by the CEO may be viewed positively by some stakeholders as it reduces company debt and shows insider commitment.

Next Steps

• The company is required to file a Current Report on Form 8-K with the SEC, including the Transaction Documents as exhibits, within four trading days.
• The company will continue to reserve sufficient shares of Common Stock for future issuances under the agreement.
• The company aims to maintain the quotation of its Common Stock on its current Trading Market and will include the issued shares in any future listing applications.
• The company may seek stockholder approval for a reverse stock split to meet listing requirements for national Trading Markets.

Key Dates

Recommendation

The capital raise and debt conversion are necessary steps for the company, but the dilution impact on existing shareholders warrants a cautious 'hold' recommendation. The lack of significant operational updates or positive financial performance in this filing prevents a more positive outlook.

Keywords

Securities Purchase Agreement, Private Placement, Capital Raise, Debt Conversion, Common Stock, Accredited Investor, Rule 506, Section 4(a)(2)